Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 01, 2015 6:53 AM ET

Biotechnology

Company Overview of Envisia Therapeutics Inc.

Company Overview

Envisia Therapeutics Inc. is engaged in the discovery and development of ocular therapeutics for the critical needs in ophthalmology. The company offers ENV515, a prostaglandin analogue that uses a biodegradable PRINT particle formulation to provide sustained intraocular pressure reduction over months. It also provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic, chemical, or other barriers that limit existing ocular therapies; therapeutics based on biocompatible polymers for the delivery of medicines with extended-release kinetics; and topical therapies for treating ocular diseases. The company was founded in 2013 and is based in Morrisville, North ...

419 Davis Drive

Suite 100

Morrisville, NC 27560

United States

Founded in 2013

Phone:

919-973-1440

Fax:

919-973-1441

Key Executives for Envisia Therapeutics Inc.

Chief Executive Officer and Director
Age: 52
President and Chief Scientific Officer
Age: 48
Executive Chairman
Age: 48
Chief Financial Officer
Chief Medical Officer
Compensation as of Fiscal Year 2014.

Envisia Therapeutics Inc. Key Developments

Envisia Therapeutics Announces Management Changes

Envisia Therapeutics announced that it has named Benjamin Yerxa, PhD as the company’s president, effective immediately. Dr. Yerxa joined Liquidia Technologies in August 2012 and was critical to the company’s formation of Envisia in November 2013 where he has since served in the dual role of chief scientific officer for both companies. Neal Fowler will remain chief executive officer of Liquidia Technologies and serve as a director on the Envisia Board of Directors. Throughout his 25-year career in the pharmaceutical and biotechnology industry, Dr. Yerxa has been involved with the discovery and development of several investigational new drugs (INDs), phase 3 clinical programs, new drug applications (NDAs) and drug approvals. His experience spans a variety of therapeutic areas including ophthalmology, pulmonary, cardiovascular and HIV. Dr. Yerxa has more than 50 U.S. patents to his name, led a variety of licensing deals and has built several R&D and corporate functions from inception. The company also announced the appointment of Gary Phillips, M.D. as executive chairman of the company’s board of directors. Dr. Phillips has been a director of the board since July 2014 and brings more than 20 years of experience in strategy, business development and licensing, commercial operations, business analytics, and clinical medicine in the pharmaceutical and healthcare industries. He is currently the senior vice president and chief strategy officer at Mallinckrodt Pharmaceuticals.

Envisia Therapeutics Inc. Initiates Phase 2a Clinical Trial for ENV515 in Patients with Glaucoma

Envisia Therapeutics Inc. announced that it has initiated a phase 2a clinical trial to investigate the safety and tolerability of its lead product, ENV515, in patients with glaucoma. ENV515 is a proprietary, fully biodegradable PRINT® (Particle Replication In Non-Wetting Templates) particle formulation of a prostaglandin analog, travoprost, with the potential for sustained intraocular pressure (IOP) reduction over as many as six months. ENV515 offers the potential to significantly address the poor compliance that exists among glaucoma patients to limit disease progression and vision loss. The progress made with ENV515 underscores the power and flexibility of the PRINT technology to rapidly develop and advance promising product candidates, simultaneously, across multiple areas of interest in ophthalmology. The phase 2a clinical trial is designed as an open-label study that will enroll 20 glaucoma patients at sites within the US. Results from this clinical trial are anticipated by mid-2015.

Envisia Therapeutics Announces Appointments to Board of Directors

Envisia Therapeutics announced that it has made two appointments to the company's board of directors. Effective immediately, Adrienne Graves, Ph.D. and Gary Phillips, M.D. will join the board as non-executive members. Dr. Graves was formerly President and Chief Executive Officer of Santen USA, a division of Santen Co. Ltd. Dr. Gary Phillips has more than 20 years' experience in strategy, business development and licensing, commercial operations, business analytics, and clinical medicine in the pharmaceutical and healthcare industries. He is currently the Senior Vice President and Chief Strategy Officer at Mallinckrodt Pharmaceuticals.

Similar Private Companies By Industry

Company Name Region
Nereus Pharmaceuticals, Inc. United States
Zumbro Discovery, Inc. United States
ZetaRx Biosciences, Inc. United States
GNI USA, Inc. United States
Vivaldi Biosciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Envisia Therapeutics Inc., please visit www.envisiatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.